ABLYNX ANNOUNCES 2016 FULL YEAR RESULTS - Seite 2

 

Additional significant clinical and regulatory catalysts anticipated in 2017:

• topline results from the Phase III HERCULES study of caplacizumab in aTTP patients expected in H2 2017

initiation of the first clinical trial of a Nanobody developed as part of the immuno-oncology collaboration with Merck & Co., Inc.

dependent on establishing a new pharmaceutical partnership, initiation of a Phase III programme in RA with vobarilizumab

at least one additional Phase I start in a partnered programme

completion of the ~300 patient systemic lupus erythematosus (SLE) study with vobarilizumab, with topline data expected in early 2018

"We have made significant progress across a number of our key clinical programmes during 2016 and continue to advance our growing pipeline of products which now has more than 45 proprietary and partnered programmes" said Dr Edwin Moses, CEO of Ablynx. "We are approaching a key inflection point with our filing for regulatory approval of caplacizumab in Europe, results from our Phase III trial expected in H2 2017 and commercial preparations well underway for the first launch of the product expected in 2018. We remain focused on delivering sustainable value to all our stakeholders and look forward to an exciting year with multiple catalysts across our extensive pipeline."

Financial highlights

(€ million)		FY 2016	FY 2015	Variance
Total revenue and grant income		85.2	77.5	10%
	R&D income	84.8	76.8	10%
	Grants	0.4	0.7	(43%)
Operating expenses		(113.8)	(94.5)	20%
	R&D	(100.3)	(83.1)	21%
	G&A	(13.5)	(11.4)	18%
Operating result		(28.6)	(17.0)	(68%)
Net financial result		27.5	(37.6)	> 100%
Net result		(1.1)	(54.5)	98%
Net cash flow		(72.2) (1)	(67.2) (3)	(7%)
Cash* at 31 December		235.4 (2)	236.2 (2)	-

       ⁽¹⁾ excluding €71.4 million net proceeds from the private placement (which raised €74.2 million, announced on 1 June 2016)